Review





Similar Products

94
Santa Cruz Biotechnology anti lamc2 antibody
(A) UMAP of all captured cells, colored by major cell type. (B) Re-clustering of the epithelial compartment resolves malignant and normal populations. (C) PCA projection of malignant cells colored by continuous KRT17 expression level, illustrating a gradient rather than a discrete bimodal distribution. (D) Hallmark pathway enrichment (normalized enrichment score, NES) in KRT17 -positive vs. KRT17 -negative malignant cells; EMT is the top-ranked pathway. Asterisks denote pathways with significant enrichment (adjusted p < 0.05). (E) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.06, FDR < 0.05). (F) Venn diagram of genes enriched in KRT17 -positive cells, KRT17 -negative cells, and the curated EMT/migration gene set, showing overlap between each group and the EMT/migration signature. (G) Volcano plot of differential EMT/migration gene expression in KRT17 -positive vs. KRT17 -negative malignant cells, with six selected EMT/migration markers (ANXA1, S100A4, GPC1, <t>LAMC2,</t> WWTR1, LAMA3) labeled. (H) Same comparison as (G) after filtering to genes with a minimum expression prevalence of 20% among malignant cells.
Anti Lamc2 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/Laminin+%CE%B3-2+Antibody/bio_rxiv__64898__2026__10__27__762113-92-15-19
Average 94 stars, based on 1 article reviews
anti lamc2 antibody - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
ABclonal Biotechnology lamc2
LPS induced activation of rat uterine fibroblasts. (A) WB detection of <t>LAMC2</t> expression levels in epithelial cells, (B) Relative expression of LAMC2 in epithelial cells, (C) Level of LAMC2 in cells detected by ELISA in epithelial cells, (D) WB detection of E-cad, N-cad, α-SMA,TGF-β1, SMAD2/3 in fibroblasts, (E) Relative expression of E-cad, N-cad, α-SMA,TGF-β1, SMAD2, SMAD3 in fibroblasts, (F) Immunofluorescence staining of COL1A1 in fibroblasts, (G) Immunofluorescence staining of COL3A1 in fibroblasts, (H) Immunofluorescence staining of α-SMA in fibroblasts, (I) Mean fluorescence intensity of COL1A1, COL3A1 and α-SMA. Compared to model in fibroblasts, * P < 0.05, ** P < 0.01.
Lamc2, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/LAMC2+Rabbit+pAb/pmc13106170-115-17-20
Average 94 stars, based on 1 article reviews
lamc2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Proteintech anti lamc2
LPS induced activation of rat uterine fibroblasts. (A) WB detection of <t>LAMC2</t> expression levels in epithelial cells, (B) Relative expression of LAMC2 in epithelial cells, (C) Level of LAMC2 in cells detected by ELISA in epithelial cells, (D) WB detection of E-cad, N-cad, α-SMA,TGF-β1, SMAD2/3 in fibroblasts, (E) Relative expression of E-cad, N-cad, α-SMA,TGF-β1, SMAD2, SMAD3 in fibroblasts, (F) Immunofluorescence staining of COL1A1 in fibroblasts, (G) Immunofluorescence staining of COL3A1 in fibroblasts, (H) Immunofluorescence staining of α-SMA in fibroblasts, (I) Mean fluorescence intensity of COL1A1, COL3A1 and α-SMA. Compared to model in fibroblasts, * P < 0.05, ** P < 0.01.
Anti Lamc2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/LAMC2+Antibody/pmc13037650-84-12-14
Average 94 stars, based on 1 article reviews
anti lamc2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Proteintech lamc2
Airway remodeling and <t>LAMC2</t> upregulation are observed in both COPD patients and mouse models. ( A ) Representative Masson’s trichrome-stained lung sections from non-smokers (n=5), smokers without COPD (n=5), and COPD patients (n=5). Scale bar: 250μm. ( B ) Quantitative staining of Masson content in non-smoker (n=5), smoker (n=5), and COPD (n=5). ( C ) Representative Masson’s trichrome staining of lung sections from air-exposed control mice (n=5) and COPD model mice (n=5). Scale bar: 100μm. ( D ) Quantitative staining of Masson content in air-control (n=5) and COPD model mice (n=5). ( E ) LAMC2 expression levels in airway epithelial cells from non-smokers (n=12), smokers (n=12), and COPD patients (n=6) based on the GSE5058 dataset. ( F ) Representative airway LAMC2 immunohistochemical staining on lung sections of non-smoker (n=5), smoker (n=5), and COPD (n=5). Scale bar: 50μm. ( G ) Quantitative staining of LAMC2 intensity on airway epithelium of non-smoker (n=5), smoker (n=5), and COPD (n=5). ( H ) LAMC2 expression levels in lung tissues from air-control (n=30) and COPD model mice (n=34) based on the GSE87292 dataset. ( I ) Western blot and ( J ) quantitative analysis of LAMC2 protein expression in the lung tissue from mice from different groups (n=3 mice/group). ( K ) Representative airway LAMC2 immunohistochemical staining on lung sections of air-control (n=5) and COPD model mice (n=5).Scale bar: 100μm. ( L ) Quantitative staining of LAMC2 intensity on airway epithelium of air-control (n=5) and COPD model mice (n=5). Data presented as the means ± SD. * P < 0.05, ** P < 0.01.
Lamc2, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/LAMC2+Antibody/pmc13037650-58-34-36
Average 94 stars, based on 1 article reviews
lamc2 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
Proteintech upa
Multi-omics integration <t>identifies</t> <t>LAMC2,</t> <t>uPA</t> and BSSP-4 as CCA-specific secreted factors. (A) Schematic of the experimental workflow to collect material for secretome and proteome analysis. (B) Venn diagram showing the overlap of PK-induced transcriptional and secretory responses in chol-orgs. Intersections include PK-upregulated genes in chol-orgs from RNA-seq (chol-PK vs chol-WT, bottom-left), PK-upregulated proteins in chol-orgs from secretome (CCM, bottom-right), genes whose PK-induced expression is stronger in interaction effects (interaction contrast, upper-right), and proteins predicted to be secreted according to the Human Protein Atlas (upper-left). (C) Bubble plot showing cross-dataset support for candidate PK-associated genes identified by the integrative analysis in (B). Rows indicate 15 selected genes from (B), and columns indicate the indicated in-house murine result and public human datasets. Dot color encodes z-scored log2 FC (z(LFC). Filled circles indicate significant differences (padj < 0.1) and open circles indicate non-significant results. Dot size reflects statistical strength-log10(padj).
Upa, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/LAMC2+Antibody/bio_rxiv__64898__2026__03__24__711280-420-10-11
Average 94 stars, based on 1 article reviews
upa - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

86
Abmart Inc anti lamc2
Multi-omics integration <t>identifies</t> <t>LAMC2,</t> <t>uPA</t> and BSSP-4 as CCA-specific secreted factors. (A) Schematic of the experimental workflow to collect material for secretome and proteome analysis. (B) Venn diagram showing the overlap of PK-induced transcriptional and secretory responses in chol-orgs. Intersections include PK-upregulated genes in chol-orgs from RNA-seq (chol-PK vs chol-WT, bottom-left), PK-upregulated proteins in chol-orgs from secretome (CCM, bottom-right), genes whose PK-induced expression is stronger in interaction effects (interaction contrast, upper-right), and proteins predicted to be secreted according to the Human Protein Atlas (upper-left). (C) Bubble plot showing cross-dataset support for candidate PK-associated genes identified by the integrative analysis in (B). Rows indicate 15 selected genes from (B), and columns indicate the indicated in-house murine result and public human datasets. Dot color encodes z-scored log2 FC (z(LFC). Filled circles indicate significant differences (padj < 0.1) and open circles indicate non-significant results. Dot size reflects statistical strength-log10(padj).
Anti Lamc2, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/anti+lamc2/pmc12928013-94-22-25
Average 86 stars, based on 1 article reviews
anti lamc2 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

94
Proteintech primary anti bodies for gapdh
Multi-omics integration <t>identifies</t> <t>LAMC2,</t> <t>uPA</t> and BSSP-4 as CCA-specific secreted factors. (A) Schematic of the experimental workflow to collect material for secretome and proteome analysis. (B) Venn diagram showing the overlap of PK-induced transcriptional and secretory responses in chol-orgs. Intersections include PK-upregulated genes in chol-orgs from RNA-seq (chol-PK vs chol-WT, bottom-left), PK-upregulated proteins in chol-orgs from secretome (CCM, bottom-right), genes whose PK-induced expression is stronger in interaction effects (interaction contrast, upper-right), and proteins predicted to be secreted according to the Human Protein Atlas (upper-left). (C) Bubble plot showing cross-dataset support for candidate PK-associated genes identified by the integrative analysis in (B). Rows indicate 15 selected genes from (B), and columns indicate the indicated in-house murine result and public human datasets. Dot color encodes z-scored log2 FC (z(LFC). Filled circles indicate significant differences (padj < 0.1) and open circles indicate non-significant results. Dot size reflects statistical strength-log10(padj).
Primary Anti Bodies For Gapdh, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+lamc2/LAMC2+Antibody/pm41644120-44-0-17
Average 94 stars, based on 1 article reviews
primary anti bodies for gapdh - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

Image Search Results


(A) UMAP of all captured cells, colored by major cell type. (B) Re-clustering of the epithelial compartment resolves malignant and normal populations. (C) PCA projection of malignant cells colored by continuous KRT17 expression level, illustrating a gradient rather than a discrete bimodal distribution. (D) Hallmark pathway enrichment (normalized enrichment score, NES) in KRT17 -positive vs. KRT17 -negative malignant cells; EMT is the top-ranked pathway. Asterisks denote pathways with significant enrichment (adjusted p < 0.05). (E) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.06, FDR < 0.05). (F) Venn diagram of genes enriched in KRT17 -positive cells, KRT17 -negative cells, and the curated EMT/migration gene set, showing overlap between each group and the EMT/migration signature. (G) Volcano plot of differential EMT/migration gene expression in KRT17 -positive vs. KRT17 -negative malignant cells, with six selected EMT/migration markers (ANXA1, S100A4, GPC1, LAMC2, WWTR1, LAMA3) labeled. (H) Same comparison as (G) after filtering to genes with a minimum expression prevalence of 20% among malignant cells.

Journal: bioRxiv

Article Title: Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma

doi: 10.64898/2026.10.27.762113

Figure Lengend Snippet: (A) UMAP of all captured cells, colored by major cell type. (B) Re-clustering of the epithelial compartment resolves malignant and normal populations. (C) PCA projection of malignant cells colored by continuous KRT17 expression level, illustrating a gradient rather than a discrete bimodal distribution. (D) Hallmark pathway enrichment (normalized enrichment score, NES) in KRT17 -positive vs. KRT17 -negative malignant cells; EMT is the top-ranked pathway. Asterisks denote pathways with significant enrichment (adjusted p < 0.05). (E) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.06, FDR < 0.05). (F) Venn diagram of genes enriched in KRT17 -positive cells, KRT17 -negative cells, and the curated EMT/migration gene set, showing overlap between each group and the EMT/migration signature. (G) Volcano plot of differential EMT/migration gene expression in KRT17 -positive vs. KRT17 -negative malignant cells, with six selected EMT/migration markers (ANXA1, S100A4, GPC1, LAMC2, WWTR1, LAMA3) labeled. (H) Same comparison as (G) after filtering to genes with a minimum expression prevalence of 20% among malignant cells.

Article Snippet: Sections were incubated with anti-K17 antibody (clone D12E5, Cell Signaling Technology, #12509, 1:800 dilution) or anti-LAMC2 antibody (clone E-6, Santa Cruz Biotechnology, sc-28330, 1:2000 dilution), detected using the VECTASTAIN Elite ABC-HRP Kit (Vector Laboratories, ref: PK-7200) and visualized with 3,3′-diaminobenzidine or DAB (ref: SK-4103-100) chromogen.

Techniques: Expressing, Migration, Gene Expression, Labeling, Comparison

(A-C) Representative H&E images of intratumoral grade I, II, and III morphology. (D-F) Corresponding dual-plex IHC for K17 (green) and LAMC2 (brown) in an adjacent serial section. (G) Relative percentage of intratumoral grade (I/II/III) per case (n = 60), ordered by percent intratumoral grade III area. (H-J) Percentage of grade area occupied by each of four K17/LAMC2 categories within grade I (H), grade II (I), and grade III (J), showing progressive enrichment of the K17-positive/LAMC2-positive category and progressive loss of the K17-negative/LAMC2-negative category with worsening grade (Friedman test with Benjamini-Hochberg-corrected pairwise comparisons; all grade-to-grade comparisons significant, adjusted p < 0.05). Scale bars, 100 μm.

Journal: bioRxiv

Article Title: Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma

doi: 10.64898/2026.10.27.762113

Figure Lengend Snippet: (A-C) Representative H&E images of intratumoral grade I, II, and III morphology. (D-F) Corresponding dual-plex IHC for K17 (green) and LAMC2 (brown) in an adjacent serial section. (G) Relative percentage of intratumoral grade (I/II/III) per case (n = 60), ordered by percent intratumoral grade III area. (H-J) Percentage of grade area occupied by each of four K17/LAMC2 categories within grade I (H), grade II (I), and grade III (J), showing progressive enrichment of the K17-positive/LAMC2-positive category and progressive loss of the K17-negative/LAMC2-negative category with worsening grade (Friedman test with Benjamini-Hochberg-corrected pairwise comparisons; all grade-to-grade comparisons significant, adjusted p < 0.05). Scale bars, 100 μm.

Article Snippet: Sections were incubated with anti-K17 antibody (clone D12E5, Cell Signaling Technology, #12509, 1:800 dilution) or anti-LAMC2 antibody (clone E-6, Santa Cruz Biotechnology, sc-28330, 1:2000 dilution), detected using the VECTASTAIN Elite ABC-HRP Kit (Vector Laboratories, ref: PK-7200) and visualized with 3,3′-diaminobenzidine or DAB (ref: SK-4103-100) chromogen.

Techniques: Morphology

(A) Leiden clustering of MACSima single-cell intensity data of all six EMT-associated markers and K17 (excluding PanCK), restricted to tumor cells, visualized by UMAP (N = 66 of 69 total cores with complete-panel staining; 410,605 tumor cells; 38 clusters). (B) K17 positivity overlaid on the same UMAP, with K17-positive cells concentrated within a discrete subset of clusters. (C) Marker enrichment across clusters ordered by K17 positivity (left) and cluster-level Spearman correlation of each marker with K17 (right): ANXA1 ρ = 0.68, LAMC2 ρ = 0.49, WWTR1 ρ = 0.24, S100A4 ρ = 0.15, LAMA3 ρ = 0.15, GPC1 ρ = −0.20. (D) Representative multiplex image showing K17 (red), LAMC2 (green), and PanCK (white) merge; arrows indicate co-expressing cells. (E) Representative multiplex image showing K17 (red), ANXA1 (green), and PanCK (white) merge; arrows indicate co-expressing cells. (F) Percentage of LAMC2-positive cells in K17-positive vs. K17-negative tumor cells (N = 67 cores, ****p < 0.0001). (G) Percentage of ANXA1-positive cells in K17-positive vs. K17-negative tumor cells (N = 69 cores, ****p < 0.0001). Boxes show the median and interquartile range, whiskers show the range, and “+” marks the mean. Wilcoxon matched-pairs signed-rank test. Scale bars, 50 μm.

Journal: bioRxiv

Article Title: Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma

doi: 10.64898/2026.10.27.762113

Figure Lengend Snippet: (A) Leiden clustering of MACSima single-cell intensity data of all six EMT-associated markers and K17 (excluding PanCK), restricted to tumor cells, visualized by UMAP (N = 66 of 69 total cores with complete-panel staining; 410,605 tumor cells; 38 clusters). (B) K17 positivity overlaid on the same UMAP, with K17-positive cells concentrated within a discrete subset of clusters. (C) Marker enrichment across clusters ordered by K17 positivity (left) and cluster-level Spearman correlation of each marker with K17 (right): ANXA1 ρ = 0.68, LAMC2 ρ = 0.49, WWTR1 ρ = 0.24, S100A4 ρ = 0.15, LAMA3 ρ = 0.15, GPC1 ρ = −0.20. (D) Representative multiplex image showing K17 (red), LAMC2 (green), and PanCK (white) merge; arrows indicate co-expressing cells. (E) Representative multiplex image showing K17 (red), ANXA1 (green), and PanCK (white) merge; arrows indicate co-expressing cells. (F) Percentage of LAMC2-positive cells in K17-positive vs. K17-negative tumor cells (N = 67 cores, ****p < 0.0001). (G) Percentage of ANXA1-positive cells in K17-positive vs. K17-negative tumor cells (N = 69 cores, ****p < 0.0001). Boxes show the median and interquartile range, whiskers show the range, and “+” marks the mean. Wilcoxon matched-pairs signed-rank test. Scale bars, 50 μm.

Article Snippet: Sections were incubated with anti-K17 antibody (clone D12E5, Cell Signaling Technology, #12509, 1:800 dilution) or anti-LAMC2 antibody (clone E-6, Santa Cruz Biotechnology, sc-28330, 1:2000 dilution), detected using the VECTASTAIN Elite ABC-HRP Kit (Vector Laboratories, ref: PK-7200) and visualized with 3,3′-diaminobenzidine or DAB (ref: SK-4103-100) chromogen.

Techniques: Single Cell, Staining, Marker, Multiplex Assay, Expressing

CPTAC proteomic analyses identify LAMC2 as the strongest protein-level correlate of K17 among the six scRNA-seq-nominated markers and associate K17/LAMC2 co-expression with adverse survival. (A) Enrichment of 27 cancer-related hallmark pathways in K17-positive vs. K17-negative tumors (140 patients; FDR < 0.05); EMT ranks first. (B) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.041; FDR = 6.21 × 10⁻²⁸; n = 158 proteins). (C) Volcano plot of differential protein abundance, K17-positive vs. K17-negative tumors; LAMC2 (log2FC = 0.676; adjusted p = 0.0002) and additional keratins/basal/EMT-associated markers are labeled among the top differentially abundant proteins. (D) K17 protein abundance correlates with LAMC2 abundance (n = 140 patients; Spearman ρ = 0.46; p = 1.61 × 10⁻⁸). (E) Kaplan-Meier overall survival by four-group K17/LAMC2 co-expression status (n = 123 patients); the K17-positive/LAMC2-positive group (n = 44 patients) shows the worst survival. (F) Forest plot of a multivariable Cox proportional hazards model for overall survival, including K17/LAMC2 co-expression groups (reference: K17-negative/LAMC2-negative) adjusted for pathologic stage and age; K17-positive/LAMC2-positive remained the only significant independent predictor of worse survival (HR = 2.53; p = 0.0013).

Journal: bioRxiv

Article Title: Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma

doi: 10.64898/2026.10.27.762113

Figure Lengend Snippet: CPTAC proteomic analyses identify LAMC2 as the strongest protein-level correlate of K17 among the six scRNA-seq-nominated markers and associate K17/LAMC2 co-expression with adverse survival. (A) Enrichment of 27 cancer-related hallmark pathways in K17-positive vs. K17-negative tumors (140 patients; FDR < 0.05); EMT ranks first. (B) GSEA enrichment plot for the Hallmark EMT gene set (NES = 3.041; FDR = 6.21 × 10⁻²⁸; n = 158 proteins). (C) Volcano plot of differential protein abundance, K17-positive vs. K17-negative tumors; LAMC2 (log2FC = 0.676; adjusted p = 0.0002) and additional keratins/basal/EMT-associated markers are labeled among the top differentially abundant proteins. (D) K17 protein abundance correlates with LAMC2 abundance (n = 140 patients; Spearman ρ = 0.46; p = 1.61 × 10⁻⁸). (E) Kaplan-Meier overall survival by four-group K17/LAMC2 co-expression status (n = 123 patients); the K17-positive/LAMC2-positive group (n = 44 patients) shows the worst survival. (F) Forest plot of a multivariable Cox proportional hazards model for overall survival, including K17/LAMC2 co-expression groups (reference: K17-negative/LAMC2-negative) adjusted for pathologic stage and age; K17-positive/LAMC2-positive remained the only significant independent predictor of worse survival (HR = 2.53; p = 0.0013).

Article Snippet: Sections were incubated with anti-K17 antibody (clone D12E5, Cell Signaling Technology, #12509, 1:800 dilution) or anti-LAMC2 antibody (clone E-6, Santa Cruz Biotechnology, sc-28330, 1:2000 dilution), detected using the VECTASTAIN Elite ABC-HRP Kit (Vector Laboratories, ref: PK-7200) and visualized with 3,3′-diaminobenzidine or DAB (ref: SK-4103-100) chromogen.

Techniques: Expressing, Quantitative Proteomics, Labeling, Significance Assay

(A-J) Representative multiplex images from ten regions of interest (ROIs), drawn from ten distinct tissue cores and ordered from lowest to highest proportion of poorly differentiated content, showing PanCK (white), K17 (red), and the six EMT/migration-associated markers: LAMC2 (green), ANXA1 (teal), S100A4 (purple), GPC1 (orange), WWTR1 (pink), LAMA3 (beige) with DAPI counterstain (blue). The progression spans predominantly glandular architecture (A) through ROIs with varying admixtures of morphology (B-I) to an ROI composed predominantly of poorly differentiated tumor cell clusters lacking glandular architecture (J). K17 is primarily observed within moderately to poorly differentiated tumor components across this progression, and along with its co-expression with LAMC2, it gives a yellow color. Scale bars, 50 μm.

Journal: bioRxiv

Article Title: Keratin 17 Defines an Epithelial-Mesenchymal Transition-Associated Migratory Cell State in Pancreatic Ductal Adenocarcinoma

doi: 10.64898/2026.10.27.762113

Figure Lengend Snippet: (A-J) Representative multiplex images from ten regions of interest (ROIs), drawn from ten distinct tissue cores and ordered from lowest to highest proportion of poorly differentiated content, showing PanCK (white), K17 (red), and the six EMT/migration-associated markers: LAMC2 (green), ANXA1 (teal), S100A4 (purple), GPC1 (orange), WWTR1 (pink), LAMA3 (beige) with DAPI counterstain (blue). The progression spans predominantly glandular architecture (A) through ROIs with varying admixtures of morphology (B-I) to an ROI composed predominantly of poorly differentiated tumor cell clusters lacking glandular architecture (J). K17 is primarily observed within moderately to poorly differentiated tumor components across this progression, and along with its co-expression with LAMC2, it gives a yellow color. Scale bars, 50 μm.

Article Snippet: Sections were incubated with anti-K17 antibody (clone D12E5, Cell Signaling Technology, #12509, 1:800 dilution) or anti-LAMC2 antibody (clone E-6, Santa Cruz Biotechnology, sc-28330, 1:2000 dilution), detected using the VECTASTAIN Elite ABC-HRP Kit (Vector Laboratories, ref: PK-7200) and visualized with 3,3′-diaminobenzidine or DAB (ref: SK-4103-100) chromogen.

Techniques: Multiplex Assay, Tissue, Migration, Morphology, Expressing

LPS induced activation of rat uterine fibroblasts. (A) WB detection of LAMC2 expression levels in epithelial cells, (B) Relative expression of LAMC2 in epithelial cells, (C) Level of LAMC2 in cells detected by ELISA in epithelial cells, (D) WB detection of E-cad, N-cad, α-SMA,TGF-β1, SMAD2/3 in fibroblasts, (E) Relative expression of E-cad, N-cad, α-SMA,TGF-β1, SMAD2, SMAD3 in fibroblasts, (F) Immunofluorescence staining of COL1A1 in fibroblasts, (G) Immunofluorescence staining of COL3A1 in fibroblasts, (H) Immunofluorescence staining of α-SMA in fibroblasts, (I) Mean fluorescence intensity of COL1A1, COL3A1 and α-SMA. Compared to model in fibroblasts, * P < 0.05, ** P < 0.01.

Journal: Frontiers in Physiology

Article Title: Molecular mechanism of Danshen injection in treating endometrial fibrosis induced by intrauterine adhesions via the LAMC2-CD44-TGF-β1-SMAD2/3 signaling pathway

doi: 10.3389/fphys.2026.1794215

Figure Lengend Snippet: LPS induced activation of rat uterine fibroblasts. (A) WB detection of LAMC2 expression levels in epithelial cells, (B) Relative expression of LAMC2 in epithelial cells, (C) Level of LAMC2 in cells detected by ELISA in epithelial cells, (D) WB detection of E-cad, N-cad, α-SMA,TGF-β1, SMAD2/3 in fibroblasts, (E) Relative expression of E-cad, N-cad, α-SMA,TGF-β1, SMAD2, SMAD3 in fibroblasts, (F) Immunofluorescence staining of COL1A1 in fibroblasts, (G) Immunofluorescence staining of COL3A1 in fibroblasts, (H) Immunofluorescence staining of α-SMA in fibroblasts, (I) Mean fluorescence intensity of COL1A1, COL3A1 and α-SMA. Compared to model in fibroblasts, * P < 0.05, ** P < 0.01.

Article Snippet: Primary antibodies: CK-19 (1:1000; YM8269, Immunoway, USA), Vimentin (1:1000; YM8324, Immunoway, USA), GAPDH (1:1000; A19056, ABclonal, China), LAMC2 (1:1000; A1869, ABclonal, China), E-cad (1:1000; A20798, ABclonal, China), N-cad (1:500; A0433, ABclonal, China), α-SMA (1:1000; A2319, ABclonal, China), TGF-β1 (1:2000; A15103, ABclonal, China), SMAD2 (1:5000; bsm-52223R, Bioss, China), SMAD3 (1:1000; A16913, ABclonal, China), p- SMAD2 (1:5000; bs-3419R, Bioss, China), p- SMAD3 (1:2000; Ap0727, ABclonal, China), and a secondary antibody (1:2000; AS014, ABclonal, China).

Techniques: Activation Assay, Expressing, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining, Fluorescence

Danshen injection improves endometrial fibrosis in IUA rats by inhibiting the LAMC2-CD44-TGF-β1- SMAD2/3 signaling pathway. (A) Uterine Weight, (B) Uterine Length, (C) Grading of intrauterine adhesions in each group, (D) Number of uterine glands, (E) Collagen volume fraction, (F) H&E Staining, (G) MASSON Staining, (H) Immunofluorescence staining of COL1A1, (I) Immunofluorescence staining of COL3A1, (J) Immunofluorescence staining of α-SMA, (K) Mean fluorescence intensity of COL1A1, COL3A1 and α-SMA, L: WB detection of LAMC2, TGF-β1, SMAD2, SMAD3, (L) Relative expression of protein LAMC2, TGF-β1, SMAD2, SMAD3. Compared to model, * P < 0.05, ** P < 0.01. For panels A-C, n = 6 independent animals per group; for panels (D–M) , n=3 independent animals per group.

Journal: Frontiers in Physiology

Article Title: Molecular mechanism of Danshen injection in treating endometrial fibrosis induced by intrauterine adhesions via the LAMC2-CD44-TGF-β1-SMAD2/3 signaling pathway

doi: 10.3389/fphys.2026.1794215

Figure Lengend Snippet: Danshen injection improves endometrial fibrosis in IUA rats by inhibiting the LAMC2-CD44-TGF-β1- SMAD2/3 signaling pathway. (A) Uterine Weight, (B) Uterine Length, (C) Grading of intrauterine adhesions in each group, (D) Number of uterine glands, (E) Collagen volume fraction, (F) H&E Staining, (G) MASSON Staining, (H) Immunofluorescence staining of COL1A1, (I) Immunofluorescence staining of COL3A1, (J) Immunofluorescence staining of α-SMA, (K) Mean fluorescence intensity of COL1A1, COL3A1 and α-SMA, L: WB detection of LAMC2, TGF-β1, SMAD2, SMAD3, (L) Relative expression of protein LAMC2, TGF-β1, SMAD2, SMAD3. Compared to model, * P < 0.05, ** P < 0.01. For panels A-C, n = 6 independent animals per group; for panels (D–M) , n=3 independent animals per group.

Article Snippet: Primary antibodies: CK-19 (1:1000; YM8269, Immunoway, USA), Vimentin (1:1000; YM8324, Immunoway, USA), GAPDH (1:1000; A19056, ABclonal, China), LAMC2 (1:1000; A1869, ABclonal, China), E-cad (1:1000; A20798, ABclonal, China), N-cad (1:500; A0433, ABclonal, China), α-SMA (1:1000; A2319, ABclonal, China), TGF-β1 (1:2000; A15103, ABclonal, China), SMAD2 (1:5000; bsm-52223R, Bioss, China), SMAD3 (1:1000; A16913, ABclonal, China), p- SMAD2 (1:5000; bs-3419R, Bioss, China), p- SMAD3 (1:2000; Ap0727, ABclonal, China), and a secondary antibody (1:2000; AS014, ABclonal, China).

Techniques: Injection, Staining, Immunofluorescence, Fluorescence, Expressing

Airway remodeling and LAMC2 upregulation are observed in both COPD patients and mouse models. ( A ) Representative Masson’s trichrome-stained lung sections from non-smokers (n=5), smokers without COPD (n=5), and COPD patients (n=5). Scale bar: 250μm. ( B ) Quantitative staining of Masson content in non-smoker (n=5), smoker (n=5), and COPD (n=5). ( C ) Representative Masson’s trichrome staining of lung sections from air-exposed control mice (n=5) and COPD model mice (n=5). Scale bar: 100μm. ( D ) Quantitative staining of Masson content in air-control (n=5) and COPD model mice (n=5). ( E ) LAMC2 expression levels in airway epithelial cells from non-smokers (n=12), smokers (n=12), and COPD patients (n=6) based on the GSE5058 dataset. ( F ) Representative airway LAMC2 immunohistochemical staining on lung sections of non-smoker (n=5), smoker (n=5), and COPD (n=5). Scale bar: 50μm. ( G ) Quantitative staining of LAMC2 intensity on airway epithelium of non-smoker (n=5), smoker (n=5), and COPD (n=5). ( H ) LAMC2 expression levels in lung tissues from air-control (n=30) and COPD model mice (n=34) based on the GSE87292 dataset. ( I ) Western blot and ( J ) quantitative analysis of LAMC2 protein expression in the lung tissue from mice from different groups (n=3 mice/group). ( K ) Representative airway LAMC2 immunohistochemical staining on lung sections of air-control (n=5) and COPD model mice (n=5).Scale bar: 100μm. ( L ) Quantitative staining of LAMC2 intensity on airway epithelium of air-control (n=5) and COPD model mice (n=5). Data presented as the means ± SD. * P < 0.05, ** P < 0.01.

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Airway remodeling and LAMC2 upregulation are observed in both COPD patients and mouse models. ( A ) Representative Masson’s trichrome-stained lung sections from non-smokers (n=5), smokers without COPD (n=5), and COPD patients (n=5). Scale bar: 250μm. ( B ) Quantitative staining of Masson content in non-smoker (n=5), smoker (n=5), and COPD (n=5). ( C ) Representative Masson’s trichrome staining of lung sections from air-exposed control mice (n=5) and COPD model mice (n=5). Scale bar: 100μm. ( D ) Quantitative staining of Masson content in air-control (n=5) and COPD model mice (n=5). ( E ) LAMC2 expression levels in airway epithelial cells from non-smokers (n=12), smokers (n=12), and COPD patients (n=6) based on the GSE5058 dataset. ( F ) Representative airway LAMC2 immunohistochemical staining on lung sections of non-smoker (n=5), smoker (n=5), and COPD (n=5). Scale bar: 50μm. ( G ) Quantitative staining of LAMC2 intensity on airway epithelium of non-smoker (n=5), smoker (n=5), and COPD (n=5). ( H ) LAMC2 expression levels in lung tissues from air-control (n=30) and COPD model mice (n=34) based on the GSE87292 dataset. ( I ) Western blot and ( J ) quantitative analysis of LAMC2 protein expression in the lung tissue from mice from different groups (n=3 mice/group). ( K ) Representative airway LAMC2 immunohistochemical staining on lung sections of air-control (n=5) and COPD model mice (n=5).Scale bar: 100μm. ( L ) Quantitative staining of LAMC2 intensity on airway epithelium of air-control (n=5) and COPD model mice (n=5). Data presented as the means ± SD. * P < 0.05, ** P < 0.01.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Staining, Control, Expressing, Immunohistochemical staining, Western Blot

Knockdown of LAMC2 attenuates airway remodeling and EMT in a COPD model. ( A ) Schematic overview of the animal experimental design and grouping. ( B ) Representative Masson staining on mice lung sections from different groups (n = 5 per group). ( C ) Quantitative staining of Masson content in different groups (n = 5 per group). ( D ) Representative airway Fibronectin immunohistochemical staining and ( E ) quantitative staining of Fibronectin intensity on lung sections of different groups (n = 5 per group). ( F ) Representative airway N-cadherin immunohistochemical staining and ( G ) quantitative staining of N-cadherin intensity on lung sections of different groups (n=5 per group). ( H ) Representative airway E-cadherin immunohistochemical staining and ( I ) quantitative staining of E-cadherin intensity on lung sections of different groups (n=5 per group). ( J – M ) Western blot analysis and quantification of EMT-related proteins (Fibronectin, N-cadherin, and E-cadherin) in lung tissues from the different treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars: 100μm.

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Knockdown of LAMC2 attenuates airway remodeling and EMT in a COPD model. ( A ) Schematic overview of the animal experimental design and grouping. ( B ) Representative Masson staining on mice lung sections from different groups (n = 5 per group). ( C ) Quantitative staining of Masson content in different groups (n = 5 per group). ( D ) Representative airway Fibronectin immunohistochemical staining and ( E ) quantitative staining of Fibronectin intensity on lung sections of different groups (n = 5 per group). ( F ) Representative airway N-cadherin immunohistochemical staining and ( G ) quantitative staining of N-cadherin intensity on lung sections of different groups (n=5 per group). ( H ) Representative airway E-cadherin immunohistochemical staining and ( I ) quantitative staining of E-cadherin intensity on lung sections of different groups (n=5 per group). ( J – M ) Western blot analysis and quantification of EMT-related proteins (Fibronectin, N-cadherin, and E-cadherin) in lung tissues from the different treatment groups. * P < 0.05, ** P < 0.01, *** P < 0.001. Scale bars: 100μm.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Knockdown, Staining, Immunohistochemical staining, Western Blot

LAMC2 expression is upregulated in bronchial epithelial cells following TGF-β1 stimulation. ( A and B ) Volcano plots illustrating DEGs from ( A ) GSE104908 and ( B ) GSE40374 datasets, with corresponding LAMC2 expression levels. Significantly upregulated genes (red) and downregulated genes (blue) are indicated (fold change >1.5, adjusted P < 0.05). ( C ) The mRNA levels of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after treatment with different concentrations of TGF-β1 for 24 hours. ( D ) Western blot and ( E – H ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after treatment with different concentrations of TGF-β1 for 24 hours. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: LAMC2 expression is upregulated in bronchial epithelial cells following TGF-β1 stimulation. ( A and B ) Volcano plots illustrating DEGs from ( A ) GSE104908 and ( B ) GSE40374 datasets, with corresponding LAMC2 expression levels. Significantly upregulated genes (red) and downregulated genes (blue) are indicated (fold change >1.5, adjusted P < 0.05). ( C ) The mRNA levels of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after treatment with different concentrations of TGF-β1 for 24 hours. ( D ) Western blot and ( E – H ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after treatment with different concentrations of TGF-β1 for 24 hours. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Expressing, Western Blot

Knockdown of LAMC2 reverses TGF-β1-induced EMT marker expression and inhibits 16HBE cell migration. ( A ) LAMC2 mRNA expression levels following transfection with different siLAMC2 constructs. ( B ) mRNA expression of Fibronectin, N-cadherin, and E-cadherin after siLAMC2 transfection and subsequent TGF-β1 treatment. ( C ) Western blot and ( D – F ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after siLAMC2 transfection and TGF-β1 treatment. ( G ) Representative images of wound healing and transwell migration assays under different treatment conditions. Scale bar: 20 μm. ( H ) Quantification of migration rate (%) from wound healing assay and ( I ) Cell migration numbers counted from transwell assays. The data are the mean ± SD. ** P < 0.01, *** P < 0.001.

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Knockdown of LAMC2 reverses TGF-β1-induced EMT marker expression and inhibits 16HBE cell migration. ( A ) LAMC2 mRNA expression levels following transfection with different siLAMC2 constructs. ( B ) mRNA expression of Fibronectin, N-cadherin, and E-cadherin after siLAMC2 transfection and subsequent TGF-β1 treatment. ( C ) Western blot and ( D – F ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after siLAMC2 transfection and TGF-β1 treatment. ( G ) Representative images of wound healing and transwell migration assays under different treatment conditions. Scale bar: 20 μm. ( H ) Quantification of migration rate (%) from wound healing assay and ( I ) Cell migration numbers counted from transwell assays. The data are the mean ± SD. ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Knockdown, Marker, Expressing, Migration, Transfection, Construct, Western Blot, Wound Healing Assay

Overexpression of LAMC2 promotes TGF-β1-induced EMT and enhances 16HBE cell migration. ( A ) LAMC2 mRNA expression levels following transfection with LAMC2 plasmid and TGF-β1treatment. ( B ) mRNA expression of Fibronectin, N-cadherin, and E-cadherin after LAMC2 plasmid vector transfection and subsequent TGF-β1 treatment. ( C ) Western blot and ( D – F ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after LAMC2 plasmid vector transfection and TGF-β1 treatment. ( G ) Representative images of wound healing and transwell migration assays under different treatment conditions. Scale bar: 20 μm. ( H ) Quantification of migration rate (%) from wound healing assay and ( I ) Cell migration numbers counted from transwell assays. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: Overexpression of LAMC2 promotes TGF-β1-induced EMT and enhances 16HBE cell migration. ( A ) LAMC2 mRNA expression levels following transfection with LAMC2 plasmid and TGF-β1treatment. ( B ) mRNA expression of Fibronectin, N-cadherin, and E-cadherin after LAMC2 plasmid vector transfection and subsequent TGF-β1 treatment. ( C ) Western blot and ( D – F ) the relative protein level of Fibronectin, N-cadherin, E-cadherin, and LAMC2 after LAMC2 plasmid vector transfection and TGF-β1 treatment. ( G ) Representative images of wound healing and transwell migration assays under different treatment conditions. Scale bar: 20 μm. ( H ) Quantification of migration rate (%) from wound healing assay and ( I ) Cell migration numbers counted from transwell assays. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Over Expression, Migration, Expressing, Transfection, Plasmid Preparation, Western Blot, Wound Healing Assay

LAMC2 facilitates EMT in 16HBE cells through activation of the AKT signaling pathway. ( A ) GO enrichment analysis of down-regulated DEGs from RNA-seq data, showing the top three most significantly enriched terms in each category: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF) (adjusted P < 0.05). Terms are ranked by gene count. ( B ) KEGG pathway analysis of down-regulated DEGs. Statistically significant pathways (adjusted P < 0.05) are visualized in a dot plot. ( C ) Western Blot and ( D ) Immunofluorescence detection, and ( E – G ) the relative protein level of AKT and p-AKT after si-NC/LAMC2 transfection and TGF-β1 treatment. ( H ) Western Blot and ( I ) Immunofluorescence detection, and ( J – L ) the relative protein level of AKT and p-AKT after LAMC2 plasmid vector transfection and TGF-β1 treatment. Scale bar: 50 μm. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: International Journal of Chronic Obstructive Pulmonary Disease

Article Title: LAMC2 Drives Airway Remodeling in COPD via EMT Regulation Through the AKT Pathway

doi: 10.2147/COPD.S580964

Figure Lengend Snippet: LAMC2 facilitates EMT in 16HBE cells through activation of the AKT signaling pathway. ( A ) GO enrichment analysis of down-regulated DEGs from RNA-seq data, showing the top three most significantly enriched terms in each category: Biological Process (BP), Cellular Component (CC), and Molecular Function (MF) (adjusted P < 0.05). Terms are ranked by gene count. ( B ) KEGG pathway analysis of down-regulated DEGs. Statistically significant pathways (adjusted P < 0.05) are visualized in a dot plot. ( C ) Western Blot and ( D ) Immunofluorescence detection, and ( E – G ) the relative protein level of AKT and p-AKT after si-NC/LAMC2 transfection and TGF-β1 treatment. ( H ) Western Blot and ( I ) Immunofluorescence detection, and ( J – L ) the relative protein level of AKT and p-AKT after LAMC2 plasmid vector transfection and TGF-β1 treatment. Scale bar: 50 μm. The data are the mean ± SD. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The membranes were blocked with 5% bovine serum albumin for 1 hour at room temperature and then incubated overnight at 4°C with the following primary antibodies: GAPDH (1:5000; Cell Signaling Technology, Danvers, MA, USA), LAMC2 (1:1000; Proteintech, China), E-Cadherin (1:1000; Cell Signaling Technology), N-Cadherin (1:1000; Cell Signaling Technology), Fibronectin (1:1000; HUABIO, China), AKT (1:1000; Cell Signaling Technology), and phospho-AKT (p-AKT, 1:1000; Cell Signaling Technology).

Techniques: Activation Assay, RNA Sequencing, Western Blot, Immunofluorescence, Transfection, Plasmid Preparation

Multi-omics integration identifies LAMC2, uPA and BSSP-4 as CCA-specific secreted factors. (A) Schematic of the experimental workflow to collect material for secretome and proteome analysis. (B) Venn diagram showing the overlap of PK-induced transcriptional and secretory responses in chol-orgs. Intersections include PK-upregulated genes in chol-orgs from RNA-seq (chol-PK vs chol-WT, bottom-left), PK-upregulated proteins in chol-orgs from secretome (CCM, bottom-right), genes whose PK-induced expression is stronger in interaction effects (interaction contrast, upper-right), and proteins predicted to be secreted according to the Human Protein Atlas (upper-left). (C) Bubble plot showing cross-dataset support for candidate PK-associated genes identified by the integrative analysis in (B). Rows indicate 15 selected genes from (B), and columns indicate the indicated in-house murine result and public human datasets. Dot color encodes z-scored log2 FC (z(LFC). Filled circles indicate significant differences (padj < 0.1) and open circles indicate non-significant results. Dot size reflects statistical strength-log10(padj).

Journal: bioRxiv

Article Title: Cell-of-Origin, not Oncogenic Effect, Determines Desmoplastic Immune Exclusion in KRAS-Driven Liver Cancer

doi: 10.64898/2026.03.24.711280

Figure Lengend Snippet: Multi-omics integration identifies LAMC2, uPA and BSSP-4 as CCA-specific secreted factors. (A) Schematic of the experimental workflow to collect material for secretome and proteome analysis. (B) Venn diagram showing the overlap of PK-induced transcriptional and secretory responses in chol-orgs. Intersections include PK-upregulated genes in chol-orgs from RNA-seq (chol-PK vs chol-WT, bottom-left), PK-upregulated proteins in chol-orgs from secretome (CCM, bottom-right), genes whose PK-induced expression is stronger in interaction effects (interaction contrast, upper-right), and proteins predicted to be secreted according to the Human Protein Atlas (upper-left). (C) Bubble plot showing cross-dataset support for candidate PK-associated genes identified by the integrative analysis in (B). Rows indicate 15 selected genes from (B), and columns indicate the indicated in-house murine result and public human datasets. Dot color encodes z-scored log2 FC (z(LFC). Filled circles indicate significant differences (padj < 0.1) and open circles indicate non-significant results. Dot size reflects statistical strength-log10(padj).

Article Snippet: The antibodies used in this study were: Lamc2 (Proteintech, #19698-1-AP), uPA (Proteintech, #17968-1-AP), BSSP4 (ThermoFisher Scientific, #PA5-47245), and rabbit-IgG (Millipore, #pp64).

Techniques: Biomarker Discovery, RNA Sequencing, Expressing

LAMC2 and uPA affect HSC activation and impair CCA formation in vivo . (A) Schematic overview of the in vitro fibroblast activation assay, where murine HSCs were treated with CCM from chol-PK and neutralizing antibodies. (B) Scatter plot indicating mRNA expression of Acta2 and Col1a1 in mHSCs treated with Chol-PK CCM and indicated neutralizing antibodies or control IgG. (n=5 from 2 independent experiments). (C) Schematic of scratch assay with mHSCs treated with low FBS (2%) media supplemented with respective recombinant protein. (D) Plot depicting mean relative wound coverage upon scratch injury over time with indicated recombinant protein at different dosage (n≥17 from 3 experiments). (E) Schematic of in vivo validation model: Chol-PK organoids were edited by CRISPR/Cas9 to generate Prss22 -, Lamc2 -, or Plau -deleted lines, which were orthotopically implanted into the liver and harvested at the same time point. (F) Macroscopic images of liver tumors 7 weeks after implantation of indicated lines. (G) Bar plot with respective tumor penetrance per line. (H) Representative histopathology images of liver tumors obtained upon orthotopic implantation of chol-PK and indicated KO lines. Stains as indicated. Red dotted line demarcates the boundary between non-tumor liver (N) and tumor (T). All scale bars are 100 μm. (I) Scatter plot depicting the total CD3 + and CD8 + T cell density per area per tumor for the indicated lines.

Journal: bioRxiv

Article Title: Cell-of-Origin, not Oncogenic Effect, Determines Desmoplastic Immune Exclusion in KRAS-Driven Liver Cancer

doi: 10.64898/2026.03.24.711280

Figure Lengend Snippet: LAMC2 and uPA affect HSC activation and impair CCA formation in vivo . (A) Schematic overview of the in vitro fibroblast activation assay, where murine HSCs were treated with CCM from chol-PK and neutralizing antibodies. (B) Scatter plot indicating mRNA expression of Acta2 and Col1a1 in mHSCs treated with Chol-PK CCM and indicated neutralizing antibodies or control IgG. (n=5 from 2 independent experiments). (C) Schematic of scratch assay with mHSCs treated with low FBS (2%) media supplemented with respective recombinant protein. (D) Plot depicting mean relative wound coverage upon scratch injury over time with indicated recombinant protein at different dosage (n≥17 from 3 experiments). (E) Schematic of in vivo validation model: Chol-PK organoids were edited by CRISPR/Cas9 to generate Prss22 -, Lamc2 -, or Plau -deleted lines, which were orthotopically implanted into the liver and harvested at the same time point. (F) Macroscopic images of liver tumors 7 weeks after implantation of indicated lines. (G) Bar plot with respective tumor penetrance per line. (H) Representative histopathology images of liver tumors obtained upon orthotopic implantation of chol-PK and indicated KO lines. Stains as indicated. Red dotted line demarcates the boundary between non-tumor liver (N) and tumor (T). All scale bars are 100 μm. (I) Scatter plot depicting the total CD3 + and CD8 + T cell density per area per tumor for the indicated lines.

Article Snippet: The antibodies used in this study were: Lamc2 (Proteintech, #19698-1-AP), uPA (Proteintech, #17968-1-AP), BSSP4 (ThermoFisher Scientific, #PA5-47245), and rabbit-IgG (Millipore, #pp64).

Techniques: Activation Assay, In Vivo, In Vitro, Expressing, Control, Wound Healing Assay, Recombinant, Biomarker Discovery, CRISPR, Histopathology